APA (7th ed.) Citation

Nie, N., Li, J., Zhang, J., Dai, J., Liu, Z., Ding, Z., . . . He, Y. (2022). First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments. Clinical Medicine Insights: Oncology, 1. https://doi.org/10.1177/11795549221134735

Chicago Style (17th ed.) Citation

Nie, Naifu, et al. "First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments." Clinical Medicine Insights: Oncology 2022: 1. https://doi.org/10.1177/11795549221134735.

MLA (9th ed.) Citation

Nie, Naifu, et al. "First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments." Clinical Medicine Insights: Oncology, 2022, p. 1, https://doi.org/10.1177/11795549221134735.